Skip to main content
Have a personal or library account? Click to login
Consideration of Drug Therapy in Benign Prostatic Hypertrophy Cover

Consideration of Drug Therapy in Benign Prostatic Hypertrophy

By:  and    
Open Access
|Jan 2015

References

  1. 1. Koch, W., Ezz, E. & de Wildt, M. (1996). The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia.. 155(1), 186-189.
  2. 2. McConnell, J., Bruskewitz, R. & Walsh, P. (1998). The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia.. 338(9), 557-563.
  3. 3. Barkin, J., Guimaraes, M. & Jacobi, G. (2003). Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alphareductase inhibitor dutasteride.. 44(4), 461-466.
  4. 4. Boyle, P. (1994). Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension.74, 18-22.
  5. 5. ⊛⊛⊛⊛⊛AUA (American Urological Association) practice guideline committee. (2004). AUA guidelines on management of benign prostatic hyperplasia.170(2 Pt 1), 530-547
  6. 6. ⊛⊛⊛⊛⊛American Urological Association. (2004).. Baltimore, USA: American Urological Association, Inc. Publishers.
  7. 7. Dahlstrand, C., Walden, M. & Deirsson, G. (1995). Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up.. 76(5), 614-618.
  8. 8. Vesely, S., Knutson, T. & Damber, J. (2003). Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms.. 37(4), 322-328.
  9. 9. Aarnink, R., Beerlage, H. & de la Rosette, J. (1998). Transrectal ultrasound of the prostate: innovations and future applications.159(5), 1568-1579.
  10. 10. Epstein, R., Lydick, E. & de Labry L. (1991). Age-related differences in risk factors for prostatectomy for benign prostatic hyperplasia: the VA Normative Aging Study.38(Suppl. 1), 9-12.
  11. 11. Andriole, G. & Kirby, R. (2003). Safety and tolerability of the Dual 5 alpha-Reductase Inhibitor dutasteride in the treatment of benign prostatic hyperplasia.44(1), 82-88.
  12. 12. Roehrborn, C., Malice, M. & Cook, T. (2001). Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials.. 58(2), 210-216.
  13. 13. Minardi, D., Garafolo, F. & Yehia, M. (2001). Pressure-flow studies in men with benign prostatic hypertrophy before and after treatment with transurethral needle ablation.. 66(2), 89-93.
  14. 14. O'Rahilly, R. & Miiller, Fabiola. (1996).(2nd ed.). New York, USA: A. John Wiley & Sons, Inc. Publication.
  15. 15. Tkocz, M. & Prajsner, A. (2002). Comparison of long-term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy.21(2), 112-116.
DOI: https://doi.org/10.2478/arsm-2014-0023 | Journal eISSN: 1841-4036 | Journal ISSN: 1223-9666
Language: English
Page range: 129 - 134
Published on: Jan 31, 2015
Published by: Ovidius University of Constanta
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2015 Diamantis G., Tode V., published by Ovidius University of Constanta
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.